Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Ticker
$PODD
Sector
Primary listing
Employees
3,900
Headquarters
Website
Insulet Metrics
BasicAdvanced
$24B
102.41
$3.32
1.35
-
Price and volume
Market cap
$24B
Beta
1.35
52-week high
$353.50
52-week low
$225.37
Average daily volume
660K
Financial strength
Current ratio
2.257
Quick ratio
1.55
Long term debt to equity
68.098
Total debt to equity
95.68
Interest coverage (TTM)
5.95%
Profitability
EBITDA (TTM)
489.2
Gross margin (TTM)
70.75%
Net profit margin (TTM)
10.01%
Operating margin (TTM)
17.26%
Effective tax rate (TTM)
12.78%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
8.02%
Return on equity (TTM)
19.18%
Valuation
Price to earnings (TTM)
102.409
Price to revenue (TTM)
10.13
Price to book
16.37
Price to tangible book (TTM)
18.3
Price to free cash flow (TTM)
60.94
Free cash flow yield (TTM)
1.64%
Free cash flow per share (TTM)
5.584
Growth
Revenue change (TTM)
25.99%
Earnings per share change (TTM)
-38.92%
3-year revenue growth (CAGR)
26.05%
10-year revenue growth (CAGR)
24.86%
3-year earnings per share growth (CAGR)
88.46%
10-year earnings per share growth (CAGR)
15.71%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Bulls say / Bears say
Insulet reported Q2 2025 revenue of $649.1 million, a 32.9% increase year-over-year (31.3% on a constant currency basis), and improved its gross margin by 190 basis points to 69.7%, surpassing previous guidance. This strong performance led the company to raise its full-year revenue growth outlook to a range of 24%–27% (Business Wire).
The Omnipod 5 App for iPhone is now fully available with integrated Dexcom G7 CGM compatibility, establishing Insulet as the first to offer a tubeless automated insulin delivery system controllable through both Android and iOS smartphones. This development broadens patient options and differentiates Insulet in the automated insulin delivery market (Business Wire; FT).
Insulet has accelerated its international growth by launching Omnipod 5 commercially in nine new countries, including Australia, Belgium, Canada, and Switzerland. The company is also advancing its new manufacturing facility in Malaysia, strengthening its global supply chain and supporting ongoing expansion (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $24B as of September 17, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 102.41 as of September 17, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.